Dogwood Therapeutics, Inc. (DWTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Dogwood Therapeutics reported revenue of $0. Net income was -$34.3M, or -$7.13 per diluted share. Operating activities generated -$15.6M of cash. At fiscal year end, Dogwood Therapeutics held $90.2M in total assets against $15.3M in total liabilities, including $6.5M of cash and equivalents.
Open the full interactive Dogwood Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Dogwood Therapeutics Key Stats
| Share Price | $1.30 |
|---|---|
| Market Cap | $44.4M |
| 52-Week Range | $1.30 – $6.82 |
| Shares Outstanding | 34.1 million (basic, 2026 Q2) |
Dogwood Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating Income | -$15.6M | -$12.3M | -$5.4M | -$12.2M | -$28.0M |
| Pre-Tax Income | -$16.0M | -$12.2M | -$5.3M | -$12.4M | -$34.0M |
| Income Tax | — | — | — | -$503 | $221,096 |
| Net Income | -$16.0M | -$12.2M | -$5.3M | -$12.3M | -$34.3M |
| Diluted EPS | -$48.00 | -$27.75 | -$7.00 | -$12.52 | -$7.13 |
Dogwood Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$15.7M | -$3.8M | -$5.0M | -$11.5M |
| Diluted EPS | -$8.20 | -$0.76 | -$0.15 | -$0.34 |
Dogwood Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $14.0M | $7.0M | $3.3M | $14.8M | $6.5M |
| Current Assets | $15.8M | $8.4M | $4.2M | $16.5M | $8.4M |
| Total Assets | $15.8M | $8.4M | $4.2M | $94.3M | $90.2M |
| Current Liabilities | $1.3M | $1.0M | $358,548 | $3.2M | $3.1M |
| Total Liabilities | $1.3M | $1.0M | $358,548 | $30.0M | $15.3M |
| Shareholders' Equity | $14.5M | $7.3M | $3.8M | -$10.1M | $74.9M |
Dogwood Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$15.7M | -$11.5M | -$4.9M | -$8.8M | -$15.6M |
| Cash From Investing | — | — | — | $3.8M | — |
| Cash From Financing | -$97,604 | $4.5M | $1.2M | $16.7M | $7.3M |
Figures from Dogwood Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Dogwood Therapeutics financials page for every line item.
Dogwood Therapeutics Company Profile
| Ticker | DWTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Alpharetta, Georgia |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001818844 |
Frequently Asked Questions
What was Dogwood Therapeutics' revenue in fiscal 2025?
Dogwood Therapeutics (DWTX) reported revenue of $0 for fiscal 2025.
What is Dogwood Therapeutics' annual revenue history?
Dogwood Therapeutics' annual revenue by fiscal year: 2023: $0; 2024: $0; 2025: $0.
What was Dogwood Therapeutics' net income in fiscal 2025?
Dogwood Therapeutics reported net income of -$34.3M for fiscal 2025.
What was Dogwood Therapeutics' earnings per share (EPS) in fiscal 2025?
Dogwood Therapeutics' diluted EPS was -$7.13 for fiscal 2025 (adjusted for any later stock splits).
What was Dogwood Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Dogwood Therapeutics reported revenue of $0.
How many shares of Dogwood Therapeutics are outstanding?
Dogwood Therapeutics reported a weighted average of 34.1 million basic shares outstanding in 2026 Q2.
What is Dogwood Therapeutics' market cap?
Based on its latest closing price, Dogwood Therapeutics (DWTX) has a market capitalization of about $44.4M.
When does Dogwood Therapeutics' fiscal year end?
Dogwood Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Dogwood Therapeutics headquartered?
Dogwood Therapeutics lists its business address in Alpharetta, Georgia in its SEC filings.